Business Model

NeurocentRx™ business model

NeurocentRx Pharma Ltd.™ aspires to be a flagship Scottish company that will facilitate the translation of world class local and international basic research into a new generation of medicines to treat chronic diseases of the nervous system.

Our innovative business model is based on several active and key components :

Our deeply embedded and intimate working practice and knowledge of local basic, clinical and translatable research teams in Scotland, along with, knowledge of and accessibility to, key accelerating tools & expertise for drug discovery and development in Scotland.
Our premise to start early, forage for and nurture opportunities, by building real and virtual management and industrial science teams around specific research and clinical opportunities where we play to our research institutes’ strengths – new mechanistic information, orphan diseases, better animal models of disease, and novel clinical insights.
It is the goal of NeurocentRx to be a pivotal integrator of collaborations that will leverage stakeholder support. In nurturing our projects, we seek pharma partners who recognise the proven strengths of the business team as a critical investment opportunity. Unlike straight and historical pharma–lab collaborations, neurocentRx will act as the broker - not just on the deal, but on the driving of projects to significant milestones and the assembly of complimentary assets.

NeurocentRx is an early stage biopharmaceutical company that has a vision to build and commercialise a robust portfolio of novel therapeutic candidates, and associated diagnostic tests, that will address major unmet clinical needs in neurological and psychiatric disorders, with an initial focus on neuropathic pain, schizophrenia and cognitive disorders.

NeurocentRx starting Ethos

It is the belief of the founders the last decade has brought many new tools to biomedical research such that advances in neurology and psychiatry are poised to accelerate at a rate some what analogous to that seen in oncology 15-20 years ago.

Just as advances in in vitro cellular and molecular biology underpinned great strides in devising new approaches to cancer therapies in the 90s, it is a confluence of completing the human genome, advances in molecular genetics, advances in combinatorial and in silico chemistry, advances in macromolecular therapeutics (antibodies), advances in biomarker discovery and imaging technologies etc that will propel development of new and successful approaches to the treatment of neurological and psychiatric disorders.

Attaining Critical Mass – Local Science, Services and Infrastructure

NeurocentRx has the opportunity to take advantage of a wealth of unexploited local and international assets, including:

Founding & Replenishable Assets:

Existing pool of high quality (5* clinical RAE 2008) but disparate assets of early stage and undervalued projects and commercially unencumbered academics - these can be assembled to create “critical mass”.

Directly and Ancillary Essential skills:

Large research and clinical footprint in neuroscience, neurology and psychiatry offers access to preclinical tools e.g. animal models, human genetics, clinical trial patients.

Biomedical R&D Infrastructure:

Growing biomedical center with new teaching hospital. Growing Alignment of Policies of Academic-Public Health-Regional and National Government. National incentives and assistance to create a sustainable local biopharmaceutical industry.